Trial Profile
SB012 for Treatment of Active Ulcerative Colitis: Prospective Multi-centre Randomised Double-blind Placebo-controlled Phase IIa Clinical Trial to Evaluate Efficacy, Pharmacokinetics, Tolerability and Safety of SB012 Enema Administered OD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-GATA3 gene-therapy (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms SECURE
- Sponsors sterna biologicals
- 05 Jun 2018 According to the sterna biologicals media release, data from this trial were presented at Digestive Disease Week.
- 05 Jun 2018 Results published in the sterna biologicals Media Release
- 29 May 2018 According to the sterna biologicals media release, data from this trial will be presented at Digestive Disease Week.